Current State-of-the-Art Therapy for Advanced Squamous Cell Lung Cancer

Scagliotti, Giorgio Vittorio; Novello, Silvia; Rapetti, Simonetta Grazia; Papotti, Mauro

doi:10.1200/edbook_am.2013.33.354

Cited by 15 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10] A single agent (mainly docetaxel) is the preferred treatment in second-line setting. [11] In our study, we analyzed clinical factors potentially infl uencing the overall outcome of patients with advanced lung SCC to identify a population of patients likely to benefi t from chemotherapy with a prolonged life expectancy. Previous publications have suggested various prognostic factors involved in advanced NSCLC using heterogeneous patient populations.…”

Section: Discussionmentioning

confidence: 99%

Squamous cell carcinoma of the lung: clinical criteria for treatment strategy

Savini¹,

Berardi²,

Mazzanti³

et al. 2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

Aim: Primary lung cancer is the leading cause of human cancer deaths worldwide, and squamous cell carcinoma (SCC) is one of the most frequent histologic subtypes. The aim of our study was to analyze clinical factors potentially affecting the overall outcome of advanced lung SCC patients. Methods: A series of 72 consecutive patients with advanced SCC undergoing chemotherapy at our institution between January 2007 and July 2013 were eligible for our analysis. Results: By univariate analysis, a better overall survival (OS) was related to response to fi rst-line chemotherapy: median OS were 19.7 vs. 7.17 months, respectively, for responders and nonresponders patients (P < 0.0001). Eastern Cooperative Oncology Group performance status, gender, and surgery were other prognostic factors. No signifi cant relationship between OS and smoking status, age, body mass index, or type of treatment was found. In the third-line setting, a better OS was associated with objective response to second-line treatment (P = 0.015). Conclusion: Our results suggest that differences in OS seem strictly associated with clinical response to previous treatments. These data should be considered in the therapeutic strategy and management of patients with SCC of the lung.

show abstract

Section: Discussionmentioning

confidence: 99%

Squamous cell carcinoma of the lung: clinical criteria for treatment strategy

Savini¹,

Berardi²,

Mazzanti³

et al. 2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

show abstract

“…For patients with poor renal function or experiencing toxicity from cisplatin, carboplatin is usually used. In local advanced unresectable or metastatic disease, doublet chemotherapy regimens (including cisplatin or carboplatin and a third-generation agent, such as gemcitabine, taxanes, or vinorelbine) remain the cornerstone of front-line systemic treatment for both AC and SCC [17,18]. Taxanes, particularly paclitaxel (in first-line setting) or docetaxel (in refractory patients) commonly complete the doublet chemotherapy regimens of platinum-based therapy for first-line treatment of CONTACT NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology

Mendes

Carreira

Baptista

et al. 2016

Expert Review of Precision Medicine and Drug Development

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality in the world, non-small lung cancer (NSCLC) is the most frequent subtype (85% of the cases). Within this subtype, adenocarcinoma and squamous cell carcinoma are the most frequent. New therapeutic strategies based on targeted delivery of drugs have relied on the use of biomarkers derived from the patients' molecular profiling. Several biomarkers have been found to be useful for use as targets for precision therapy in NSCLC, such as mutations in the epidermal growth factor receptor, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, anaplastic lymphoma kinase, mesenchymal-epithelial transition factor receptor tyrosine kinase, BRAF, c-ros oncogene 1, P53 and phosphatase with tensin homology. Current developments in Nanomedicine have allowed for multifunctional systems capable of delivering therapeutics with increased precision to the target site/tissue, while simultaneously assisting in diagnosis. Here, we review the use of biomarkers in nanotechnology translation in NSCLC management. ARTICLE HISTORY

show abstract

“…Consequently, patients are particularly prone to such symptoms as dyspnea, cough, obstructive pneumonia, and hemoptysis 10. The predisposition to hemoptysis in particular limits the use of antiangiogenic agents, such as bevacizumab, in this setting 10–12…”

Section: Introductionmentioning

confidence: 99%

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

Hirsh¹

2017

OTT

View full text Add to dashboard Cite

Until recently, few treatment options existed for the treatment of squamous cell carcinoma (SqCC) of the lung, especially in the second-line setting following platinum-based chemotherapy. Accordingly, outcomes in this subtype of non-small-cell lung cancer (NSCLC) were generally poor. In this context, the recent availability of the checkpoint inhibitors nivolumab and pembrolizumab, the anti-VEGFR2 antibody ramucirumab (combined with docetaxel), and the ErbB-family blocker afatinib for the treatment of relapsed/refractory SqCC of the lung represent major advances. However, the rapid expansion of the treatment armamentarium invites many questions regarding optimal treatment choice and sequence in individual patients. This review focuses on the biologic rationale and clinical evidence to support the use of afatinib in this treatment setting, highlighting the prominent role of the ErbB-signaling cascade in SqCC tumors. The seminal Phase III LUX-Lung 8 study, on which the approval of afatinib is based, is discussed and contextualized with the emergence of immunotherapies. Finally, criteria are explored that might drive physicians’ treatment decisions when considering the use of afatinib based on individual patient characteristics. Other ongoing developments in the treatment of SqCC of the lung that will lead to further options and welcome improvements in the management of this difficult-to-treat disease are summarized.

show abstract

Current State-of-the-Art Therapy for Advanced Squamous Cell Lung Cancer

Cited by 15 publications

References 28 publications

Squamous cell carcinoma of the lung: clinical criteria for treatment strategy

Squamous cell carcinoma of the lung: clinical criteria for treatment strategy

Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

Contact Info

Product

Resources

About